These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 36169412)

  • 1. Neutralization of SARS-CoV-2 Omicron and Delta Variants in Relation to Vaccine-Induced Antibody Levels in Kidney Transplant Recipients and Healthy Controls.
    Pedersen RM; Bang LL; Tornby DS; Kierkegaard H; Nilsson AC; Johansen IS; Sydenham TV; Jensen TG; Justesen US; ; Bistrup C; Andersen TE
    Microbiol Spectr; 2022 Oct; 10(5):e0131422. PubMed ID: 36169412
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Kim H; Reineke M; Beimler J; Buylaert M; Nusshag C; Kälble F; Reichel P; Töllner M; Schaier M; Klein K; Benes V; Rausch T; Rieger S; Stich M; Tönshoff B; Weidner N; Schnitzler P; Zeier M; Süsal C; Hien Tran T; Bartenschlager R; Speer C
    Am J Transplant; 2022 Jul; 22(7):1873-1883. PubMed ID: 35384272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination.
    Benning L; Morath C; Bartenschlager M; Nusshag C; Kälble F; Buylaert M; Schaier M; Beimler J; Klein K; Grenz J; Reichel P; Hidmark A; Ponath G; Töllner M; Reineke M; Rieger S; Tönshoff B; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
    Clin J Am Soc Nephrol; 2022 Jan; 17(1):98-106. PubMed ID: 34937771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients.
    Benotmane I; Bruel T; Planas D; Fafi-Kremer S; Schwartz O; Caillard S
    Kidney Int; 2022 May; 101(5):1073-1076. PubMed ID: 35231463
    [No Abstract]   [Full Text] [Related]  

  • 6. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
    Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays.
    Ferré VM; Lebourgeois S; Chenane HR; Menidjel R; Masson C; Collin G; Visseaux B; Descamps D; Fidouh N; Charpentier C
    J Infect; 2022 Jun; 84(6):834-872. PubMed ID: 35278483
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern.
    Wang H; Chen Z; Wang Z; Li J; Yan Z; Yuan J; Zhu A; Chen L; Liu Y; Hu C; Zhu A; Li G; Li Y; Deng J; Ma L; Sui X; Miao W; Li J; Zheng X; Piao J; Yao Y; Rao J; Shan C; Yuan Z; Zhao J; Zhu T
    Emerg Microbes Infect; 2022 Dec; 11(1):1550-1553. PubMed ID: 35604772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients.
    Al Jurdi A; Gassen RB; Borges TJ; Lape IT; Morena L; Efe O; Solhjou Z; El Fekih R; Deban C; Bohan B; Pattanayak V; Kotton CN; Azzi JR; Riella LV
    Kidney Int; 2022 Jun; 101(6):1282-1286. PubMed ID: 35429496
    [No Abstract]   [Full Text] [Related]  

  • 16. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial.
    Kumar D; Ferreira VH; Hall VG; Hu Q; Samson R; Ku T; Ierullo M; Majchrzak-Kita B; Tomlinson G; Gingras AC; Humar A
    Ann Intern Med; 2022 Feb; 175(2):226-233. PubMed ID: 34807716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
    Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
    Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
    Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
    Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.